Open-label study to assess the pharmacokinetics, safety and tolerability of siponimod in healthy subjects with CYP2C9 extensive (EM) and poor metabolizer (PM) phenotype.
Phase of Trial: Phase I
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Siponimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Status changed from not yet recruiting to completed, as per results presented at the 68th Annual Meeting of the American Academy of Neurology.
- 19 Jun 2013 New trial record